PIPC Joins 30 Leading Disability and Civil Rights Stakeholders in Letter Asking HHS to Step Up Nondiscrimination Efforts
60 Patient and Disability Groups Join PIPC in Comment Letter to HHS Opposing Most Favored Nations Rule
In a letter to the Institute for Clinical and Economic Review (ICER), Partnership to Improve Patient Care (PIPC) Chairman Tony Coelho provided feedback on ICER’s draft evidence report for high cholesterol treatments.
More than 40 Leading Patient and Disability Groups Join PIPC Comment Letter on PCORI Outcome Principles
Over 40 leading groups and individuals representing the patient and disability communities signed onto the Partnership to Improve Patient Care's (PIPC) comment letter to the Patient-Centered Outcomes Research Institute (PCORI) on its Proposed Principles for the Consideration of the Full Range of Outcomes Data. The letter applauds Executive Director Nakela Cook for recognizing the PCORI authorizing statue's prohibition on cost-effective analysis, thus protecting patients from harmful and restrictive coverage decisions. The letter also emphasizes three key recommendations to PCORI, including: (1) promote usability of collected information for decision-making, including patients with multiple chronic conditions and their caregivers; (2) contextualize the cost information being communicated to ensure it is not used against patients and providers; and (3) solicit and appoint new Methodology Committee members who have appropriate expertise in the collection and communication of patient-level data.
Amidst the debate around value driven health care, it is important to understand what organizations can support such a system. Two prominent organizations, the Patient-Centered Outcomes Research Institute (PCORI) and the Institute for Clinical and Economic Review (ICER), are positioned to help decision makers compare available treatment options. However, their approaches differ significantly.
The Partnership to Improve Patient Care (PIPC) submitted a comment letter to the Institute for Clinical and Economic Review (ICER) on its draft evidence report for bladder cancer treatments. PIPC Chairman Tony Coelho criticized ICER for continuing to conduct studies prematurely, as well as assessing the value-based price of these drugs in the absence of sufficient evidence. Chairman Coelho also noted that the mixed data sources for measures of effectiveness in the report are likely to lead to biased estimates in ICER's model. "Bladder cancer can present many challenges to a patient’s quality of life, and there are currently very few treatment options for patients with high-risk non-muscle invasive bladder cancer that is unresponsive to BCG," wrote Chairman Coelho. "It is critical that new treatments are evaluated carefully when there is appropriate available evidence."